In previous clinical trials and studies of HDAC inhibitors in SMA patients and animal models, the beneficial effects have been attributed to the increase in SMN transcript and protein levels [13], [26], [15], [27]. This evidence concerns the gene HDAC9 and proximal spinal muscular atrophy.